4.18
-0.12(-2.79%)
Currency In USD
| Previous Close | 4.3 |
| Open | 4.32 |
| Day High | 4.35 |
| Day Low | 4.18 |
| 52-Week High | 11.55 |
| 52-Week Low | 1.47 |
| Volume | 178,727 |
| Average Volume | 3.02M |
| Market Cap | 102.6M |
| PE | -3.37 |
| EPS | -1.24 |
| Moving Average 50 Days | 3.93 |
| Moving Average 200 Days | 2.93 |
| Change | -0.12 |
If you invested $1000 in Artiva Biotherapeutics, Inc. (ARTV) since IPO date, it would be worth $348.33 as of December 28, 2025 at a share price of $4.18. Whereas If you bought $1000 worth of Artiva Biotherapeutics, Inc. (ARTV) shares 6 months ago, it would be worth $2,768.21 as of December 28, 2025 at a share price of $4.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease
GlobeNewswire Inc.
Nov 12, 2025 12:20 PM GMT
32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoff All patients received AlloNK as outpatients, and the majority were treated in community rheumatology trial sites with
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®
GlobeNewswire Inc.
Nov 03, 2025 9:05 PM GMT
The virtual webcast will take place Wednesday, November 12, 2025, at 8 a.m. ET Initial safety data for 32 patients with autoimmune disease treated with AlloNK + monoclonal antibody (mAb) therapy, highlighting a favorable tolerability profile observed
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November
GlobeNewswire Inc.
Oct 30, 2025 8:17 PM GMT
SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune di